NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RAPP

Rapport Therapeutics Inc

Jul 11 • 04:00PM ET

14.60

Dollar change -0.78
Percentage change -5.07	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX BLUE REGN SAGE NBIX ACAD MRNA CRSP EDIT

| Held by: IWM VTI IWN IBB VXF VTWO SCHA IWC VHT SBIO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.20	Insider Own	52.20%	Shs Outstand	36.50M	Perf Week	21.26%
Market Cap	532.87M	Forward P/E	-	EPS next Y	-4.31	Insider Trans	-0.09%	Shs Float	17.45M	Perf Month	10.94%
Enterprise Value	255.22M	PEG	-	EPS next Q	-0.83	Inst Own	58.78%	Short Float	16.21%	Perf Quarter	62.58%
Income	-79.70M	P/S	-	EPS this Y	13.10%	Inst Trans	10.05%	Short Ratio	16.46	Perf Half Y	-17.91%
Sales	0.00M	P/B	1.86	EPS next Y	-31.28%	ROA	-31.36%	Short Interest	2.83M	Perf YTD	-17.70%
Book/sh	7.83	P/C	1.87	EPS next 5Y	-8.86%	ROE	-33.14%	52W High	29.74 -50.91%	Perf Year	-43.56%
Cash/sh	7.82	P/FCF	-	EPS past 3/5Y	-171.13% -	ROIC	-27.23%	52W Low	6.43 127.06%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.59% 8.68%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	31.01	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	67.10	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	31.01	EPS Q/Q	-10.08%	SMA20	21.75%	Beta	0.46	Target Price	35.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	29.72%	Rel Volume	0.83	Prev Close	15.38
Employees	69	LT Debt/Eq	0.02	Earnings	May 08 BMO	SMA200	-5.29%	Avg Volume	171.82K	Price	14.60
IPO	Jun 07, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.53% -	Trades		Volume	142,758	Change	-5.07%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	TD Cowen	Buy
Jul-02-24	Initiated	Stifel	Buy	$35
Jul-02-24	Initiated	Jefferies	Buy	$35

Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat) -7.93%
Jun-02-25 02:45PM	Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates (GlobeNewswire) +13.66%
May-27-25 07:00AM	Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) -7.21%
May-21-25 07:00AM	Rapport Therapeutics to Host 2025 Investor and Analyst Day (GlobeNewswire)
May-08-25 07:00AM	Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
Apr-22-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.27%
Mar-31-25 04:33AM	Rapport Therapeutics: Too Early To Be Interesting (Seeking Alpha)
Mar-21-25 07:00AM	Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-11-25 07:00AM	Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +8.34%
Mar-03-25 07:00AM	Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development (GlobeNewswire) -28.71%
Feb-24-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-10-25 07:20AM	Rapport Therapeutics announces new Phase 1 data for RAP-219 (TipRanks) -11.26%
Jan-09-25 09:12AM	CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
07:00AM	Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
Dec-06-24 12:01PM	Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures (GlobeNewswire)
07:00AM	Loading…
Nov-14-24 07:00AM	Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-08-24 07:18AM	Rapport Therapeutics expects cash to fund requirements through 2026 (TipRanks)
Nov-07-24 07:00AM	Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update (GlobeNewswire)
Nov-04-24 07:00AM	Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November (GlobeNewswire)
Sep-05-24 07:00AM	Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences (GlobeNewswire)
Aug-29-24 07:00AM	Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire)
Aug-08-24 07:00AM	Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update (GlobeNewswire)
Aug-06-24 06:30AM	3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns (InvestorPlace)
Jul-29-24 07:00AM	Rapport Therapeutics to Present Data for TARP 8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain (GlobeNewswire)
Jul-05-24 02:22PM	Hedge Fund and Insider Trading News: Bill Ackman, Segantii Capital Management Ltd, Rapport Therapeutics Inc (RAPP), Archer Aviation Inc (ACHR), and More (Insider Monkey)
Jun-12-24 04:01PM	Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire) +9.02%
Jun-06-24 06:54PM	Rapport Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bredt David	Chief Scientific Officer	Jun 16 '25	Sale	11.00	8,500	93,522	443,642	Jun 18 04:15 PM
DAVID BREDT	Officer	Jun 16 '25	Proposed Sale	11.19	34,000	380,460		Jun 16 04:24 PM
Bredt David	Chief Scientific Officer	May 15 '25	Sale	9.56	8,500	81,262	452,142	May 19 04:30 PM
Bredt David	Chief Scientific Officer	Apr 15 '25	Sale	9.57	8,500	81,310	460,642	Apr 16 05:00 PM
Bredt David	Chief Scientific Officer	Mar 14 '25	Sale	10.85	8,500	92,205	469,142	Mar 17 05:00 PM
DAVID BREDT	Officer	Mar 14 '25	Proposed Sale	10.02	25,500	255,510		Mar 14 04:20 PM
Ignelzi Troy A.	Chief Financial Officer	Mar 12 '25	Buy	10.10	9,900	99,990	9,900	Mar 13 05:13 PM
Ignelzi Troy A.	Chief Financial Officer	Mar 13 '25	Buy	9.98	100	998	10,000	Mar 13 05:13 PM
Young Wendy B.	Director	Mar 12 '25	Buy	10.21	6,000	61,250	6,000	Mar 13 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RAPP

Rapport Therapeutics Inc

Upgrade your FINVIZ experience